Fairvalue-Calculator Fairvalue-Calculator
EN DE

BLUEMTEC Co (439580) Fair Value & Analysis

Healthcare · KR · Market cap 82.9B KRW

Price1,978 KRW
Fair Value523.50 KRW
Upside-73.5%
Quality95/100
Evidence: Medium Range 172.95 KRW – 874.05 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

BLUEMTEC Co (439580) currently trades at 1,978 KRW, while our model-based Fair Value estimate is 523.50 KRW — implying the stock looks roughly 73.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

BLUEMTEC Co., Ltd. operates a pharmaceutical distribution platform in South Korea and internationally. It is also involved in the healthcare digital marketing, IT development, fulfilment, pharmaceutical distribution data, and medical staff matching, and logistics businesses. The company was founded in 2015 and is headquartered in Yongin-si, South Korea.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +920% Alibaba Health Information Technology Limited (ALBBY) -19% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +23% Sugi Holdings (SGIPF) +295%

Frequently asked questions

Is BLUEMTEC Co (439580) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 523.50 KRW versus a price of 1,978 KRW — about −74% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 439580?
Our 21-model fair value for BLUEMTEC Co is 523.50 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 1,978 KRW.
What is the quality score of 439580?
BLUEMTEC Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.